GPC3 and hepatocellular carcinoma: A further investigation from Labadie et al. evaluated a GPC3-targeted theranostic platform for HCC using the same mAb (i.e., αGPC3), conjugated with 89Zr (89Zr-αGPC3) for PET imaging and 90Y (90Y-αGPC3) for radioimmunotherapy [32].